• 1
    Alter M, Kruszon-Moran D, Nainan O, et al. The prevalence of hepatitis C infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 55662.
  • 2
    Bhattacharya R, Shuhart M. Hepatitis C and alcohol: interactions, outcomes and implications. J Clin Gastroenterol 2003; 36: 24252.
  • 3
    Oshita M, Hayashi N, Kasahara A, et al. Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C. Hepatology 1994; 27: 17305.
  • 4
    Okazaki T, Yoshihara H, Suzuki K, et al. Efficacy of interferon therapy in patients with chronic hepatitis C. A comparison between nondrinkers and drinkers. Scand J Gastroenterol 1994; 29: 103943.
  • 5
    Ohnishi K, Matsuo S, Matsutani K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996; 91: 13749.
  • 6
    Tabone M, Sidoli L, Laudi C, et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J Viral Hepat 2002; 9: 28894.
  • 7
    Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 44351.
  • 8
    Fried M, Shiffman M, Reddy K, et al. Peg interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 9
    Mukamal K, Conigrave K, Mittleman M, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003; 348: 10918.
  • 10
    Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004; 39: 82634.
  • 11
    Pearlman BL. Hepatitis C treatment update. Am J Med 2004; 117: 34452.
  • 12
    Alcoholic Beverages; USDA Dietary Guidelines for Americans 2005. Available from:
  • 13
    Hadziyannis S, Sette H Jr, Morgan T, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 14
    Muir A, Bornstein J, Killenberg P, et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 226571.
  • 15
    Kim WR, Potarucha JJ, Benson JT, Therneau TM. The impact of competing risks on the observed rate of hepatitis C progression. Gastroenterology 2004; 127: 74955.
  • 16
    Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 260917.
  • 17
    Bhattacharya R, Shuhart M. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36: 24252.
  • 18
    Safdar K, Schiff E. Alcohol and hepatitis C. Semin Liver Dis 2004; 24: 30515.